证券代码：688137 证券简称：近岸蛋白 公告编号：2025-029 苏州近岸蛋白质科技股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/9/28 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 10 10 | 月 | 15 | 日~2025 | 年 | 月 | 14 日 | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 0万股 | | | | | | | | 累计已回购股数占总股本比例 | 0% | | | | | | | | 累计已回购金额 | 0万元 | | | | | | | | ...

Market Overview - The biopharmaceutical sector increased by 0.55% on August 4, with Sairun Biotech leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Top Gainers in Biopharmaceutical Sector - Sairun Biotech (688163) closed at 27.37, up 11.90% with a trading volume of 72,700 shares and a transaction value of 190 million [1] - Xizang Pharmaceutical (600211) closed at 46.19, up 10.00% with a trading volume of 321,400 shares and a transaction value of 1.451 billion [1] - Wanze Shares (000534) closed at 17.31, up 9.97% with a trading volume of 598,100 shares and a transaction value of 1.018 billion [1] - Other notable gainers include Saiseng Pharmaceutical (300485) and Sanyuan Gene (837344) with increases of 7.45% and 6.89% respectively [1] Top Losers in Biopharmaceutical Sector - Kexing Pharmaceutical (688136) closed at 50.20, down 9.42% with a trading volume of 129,900 shares and a transaction value of 655 million [2] - Aopumai (688293) closed at 57.00, down 6.56% with a trading volume of 20,800 shares and a transaction value of 119 million [2] - Other significant decliners include Wuxi Jinghai (836547) and Olin Biotech (688319) with decreases of 3.28% and 3.22% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net inflow of 10.35 million from institutional investors, while retail investors contributed a net inflow of 250 million [2][3] - Notable net inflows from individual stocks include Ganjin Pharmaceutical (603087) with 18.6 million and Xizang Pharmaceutical (600211) with 12.1 million [3] - Conversely, significant net outflows were observed in stocks like Xizang Pharmaceutical and Wanze Shares, indicating a mixed sentiment among retail investors [3]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 secretaries earned over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for secretaries in the A-share biopharmaceutical sector is 1.01 million yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] Age and Education Distribution - The age distribution of secretaries shows that those aged 40-50 constitute 61%, while those over 50 account for 15%, and those aged 30-40 make up 18% [1] - In terms of education, 52% of secretaries hold a bachelor's degree, while 44% have a master's degree, and only 2% possess a doctoral degree [3] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [7] - The top five companies with the highest number of investor meetings are: Bohui Innovation (1,500 meetings), Jindike (777 meetings), Nearshore Protein (681 meetings), Sailun Biotech (549 meetings), and Kanghua Biotech (504 meetings) [9]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for company secretaries in the biopharmaceutical sector is 1.01 million yuan, with the distribution of salaries as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] - The top five highest-paid company secretaries have salaries of 3.2565 million yuan, 2.5345 million yuan, 2.2809 million yuan, 1.9265 million yuan, and 1.89 million yuan, with their tenure at the companies ranging from less than one year to 15 years [7] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 61%, while those over 50 account for 15%, and those under 30 make up 6% [1][3] - The educational background indicates that 52% hold a bachelor's degree, 44% have a master's degree, and only 2% possess a doctoral degree, with the latter represented by just one individual [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually, while only 2% have more than 1,000 meetings [9] - The five companies with the highest number of investor meetings are reported to have 1,500, 777, 681, 549, and 504 meetings, respectively [9]

Group 1 - The core point of the article highlights the financing activities related to Nearshore Protein, indicating a net buying trend in recent trading days [1] - On July 29, Nearshore Protein had a financing buy amount of 0.11 billion, ranking 1284th in the two markets, with a financing repayment amount of 0.10 billion, resulting in a net buy of 287,400 [1] - Over the last three trading days from July 25 to July 29, Nearshore Protein received financing buy amounts of 0.17 billion, 0.14 billion, and 0.11 billion respectively [1] Group 2 - In terms of securities lending, on July 29, there were no shares sold short, resulting in a net short sale of 0.00 shares [1]

Summary of Key Points Core Viewpoint - The company, Suzhou Nearshore Protein Technology Co., Ltd., has announced a share repurchase plan aimed at utilizing excess funds from its initial public offering for employee stock ownership plans or equity incentives, with a total expected repurchase amount between 10 million to 20 million RMB [1][2]. Group 1: Repurchase Plan Details - The repurchase plan was first disclosed on July 30, 2024, and is set to be implemented from July 27, 2024, to July 26, 2025 [1]. - The maximum repurchase price is set at 47.00 RMB per share [1]. - The actual number of shares repurchased is 404,337, which accounts for 0.5762% of the total share capital [1][2]. Group 2: Financial Aspects of the Repurchase - The total amount spent on the repurchase is 11.956 million RMB, with the repurchase price ranging from 28.75 RMB to 35.51 RMB per share [2][3]. - The funds used for the repurchase come from excess funds raised during the company's initial public offering, ensuring no significant impact on the company's operational activities or financial status [3]. Group 3: Share Distribution Changes - Before the repurchase, the company had 70,175,439 shares in total, which remains unchanged post-repurchase [4]. - The repurchased shares will be used for employee stock ownership plans or equity incentives, and if not transferred within three years, the company will follow legal procedures to reduce its registered capital [4][5]. Group 4: Compliance and Governance - The company has confirmed that the execution of the repurchase plan aligns with the board's approved proposal, and there are no discrepancies [3]. - During the repurchase period, there were no stock trading activities by the company's directors, supervisors, senior management, or major shareholders [3].

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-028 苏州近岸蛋白质科技股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/7/30 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 7 年 7 月 | 月 | 27 | 日~2025 | 26 日 | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | 回购价格上限 | 47.00元/股 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 实际回购股数 | 404,337股 | | | | | | 实际回购股数占总股本比例 | 0.5762% | | | | | | 实际回购金额 | 1,195.609120万元 | ...

Market Performance - The Sci-Tech Innovation Board (STAR Market) index rose by 0.14%, closing at 997.63 points, with a total trading volume of 2.974 billion shares and a turnover of 109.12 billion yuan, resulting in a weighted average turnover rate of 1.66% [1] - Among the tradable stocks on the STAR Market, 379 stocks closed higher, with 4 stocks experiencing a rise of over 10%, including Puyuan Information and Shuangwei New Materials, which hit the daily limit [1] - The distribution of turnover rates shows that 14 stocks had turnover rates between 10% and 20%, 62 stocks between 5% and 10%, 88 stocks between 3% and 5%, 289 stocks between 1% and 3%, and 136 stocks had turnover rates below 1% [1] Individual Stock Performance - The stock with the highest turnover rate was Nearshore Protein, which closed down by 6.48% with a turnover rate of 17.94% and a transaction amount of 264 million yuan [1] - Yitang Co., Ltd. closed up by 0.84% with a turnover rate of 14.75% and a transaction amount of 607 million yuan [1] - Other notable stocks with high turnover rates include Qingyun Technology, Hongwei Technology, and Borui Data, with turnover rates of 14.75%, 14.28%, and 12.71% respectively [1] Sector Analysis - In terms of sector performance, the computer industry had the most stocks with a turnover rate exceeding 5%, totaling 20 stocks, followed by the pharmaceutical and biological sector with 16 stocks, and the electronics sector with 13 stocks [3] - Among the high turnover stocks, 48 experienced net inflows of main funds, with significant inflows seen in Gaomei Co., Ltd., Yuanjie Technology, and Puyuan Information, with net inflows of 76.81 million yuan, 64.81 million yuan, and 62.93 million yuan respectively [3] - Conversely, stocks with significant net outflows included Juxin Technology, Huafeng Technology, and Shijia Photon, with net outflows of 93.57 million yuan, 59.44 million yuan, and 51.91 million yuan respectively [3] Notable Stocks on July 16 - The following stocks had notable performance on July 16: - Nearshore Protein: latest closing price 45.45 yuan, daily change -6.48%, turnover rate 17.94%, net outflow -25.89 million yuan [4] - Yitang Co., Ltd.: latest closing price 20.44 yuan, daily change 0.84%, turnover rate 14.75%, net outflow -25.10 million yuan [4] - Puyuan Information: latest closing price 28.43 yuan, daily change 20.01%, turnover rate 11.33%, net inflow 62.93 million yuan [4]

Group 1 - Nearshore Protein (688137.SH) announced a share reduction plan by shareholders holding less than 5% of the company's shares [1] - Shareholder Heze Qiaobei plans to reduce holdings by up to 161,959 shares, representing a maximum of 0.2308% of total shares [2] - Shareholder Shanghai Pujin plans to reduce holdings by up to 263,158 shares, representing a maximum of 0.3750% of total shares [2] Group 2 - The reduction period for both shareholders is from July 14, 2025, to October 13, 2025 [2] - The shares to be reduced were acquired before the IPO, and the reason for the reduction is for their own operational development needs [2] - Nearshore Protein was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 29, 2022, with an initial offering price of 106.19 yuan per share [3] Group 3 - The total amount raised from the IPO was 1.8629825 billion yuan, with a net amount of 1.7421958 billion yuan after deducting issuance costs [3][4] - The company initially planned to raise 1.5 billion yuan, with the funds allocated for core diagnostic materials, innovative diagnostic reagent industrialization projects, research center construction, and working capital [4]

Core Viewpoint - The announcement details the share reduction plans of shareholders holding less than 5% of Suzhou Nearshore Protein Technology Co., Ltd, specifically Shanghai Qiaobei Investment Management Partnership and Shanghai Pujin Technology Development Partnership, due to their operational and funding needs [1][2]. Shareholder Holding Information - Shareholder Shanghai Qiaobei holds 795,292 shares, representing 1.1333% of the total share capital of the company [1][2]. - Shareholder Shanghai Pujin holds 263,158 shares, representing 0.3750% of the total share capital of the company [2][3]. Reduction Plan Details - Shanghai Qiaobei plans to reduce its holdings by up to 161,959 shares, which is a maximum of 0.2308% of the total shares, through centralized bidding and block trading from July 14, 2025, to October 13, 2025 [3]. - Shanghai Pujin plans to reduce its holdings by up to 263,158 shares, which is a maximum of 0.3750% of the total shares, through similar methods and during the same period [3]. Compliance and Commitments - The reduction plan is in compliance with the commitments made in the prospectus regarding advance notice of share reductions [2][4]. - The shareholders have committed to adhere to relevant laws and regulations regarding share transfers and reductions, ensuring that the reduction does not affect the company's governance structure or ongoing operations significantly [4].